PAYER POLICY CHANGES

C9081 Insurance Policy Changes

HCPCS C9081 is officially defined as "Idecabtagene vicleucel, up to 460 million autologous anti-bcma car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose." HCPCS C9081 is referenced in 1 tracked payer policy change from Premera Blue Cross. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS C9081 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Watch C9081

Get one email when a payer policy names C9081, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

See every payer rule for C9081

Prior authorization lists, coverage criteria, NCCI edits and Medicare coverage articles for C9081 in one place.

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.